Close Menu

NEW YORK – Dutch startup Cyclomics is developing a liquid biopsy test for tumor recurrence and therapy response monitoring that it says will be the first to use nanopore sequencing technology.

The company, a 2018 spinout from University Medical Center Utrecht, where it is currently incubated, has developed a technology that combines rolling circle amplification of target genes with sequencing on Oxford Nanopore's MinIon sequencer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.